Items tagged with Drug-resistant TB
Outcomes of concomitant bedaquiline and delamanid in patients with multidrug-resistant TB (post)
Concomitant treatment with bedaquiline and delamanid (Bdq-Dlm) was determined to be safe and effective and did not increase the risk for cardiotoxicity in patients with multidrug- and rifampicin-resistant (MDR/RR) tuberculosis (TB) infection, according to results of a study published in Clinical Infectious Diseases.
Meropenem plus clavulanate and rifampin for treatment of drug-resistant TB (post)
Results of a study called into question the recommendation for meropenem with amoxicillin and clavulanate to be used as a second-line therapy for drug-resistant tuberculosis (TB). These findings were published in the American Journal of Respiratory and Critical Care Medicine.
RESIST-TB March 2022 newsletter (post)
RESIST-TB released its March 2022 newsletter with the latest research publications on drug-resistant TB.
Episode 5 of WGND podcast now available online (post)
Episode 5 of the podcast series, The Dose, by the Stop TB Partnership's Working Group on New TB Drugs (WGND) is now available online. Shobha Shukla speaks with two experts on highly drug-resistant TB, Dr. Francesca Conradie and Dr. Gustavo Velásquez, on the results from ZeNix, a Phase 3 clinical trial exploring potential optimization of a regimen for treating patients with highly drug-resistant TB.
Webinar: Discussion of 6-month MDR-TB treatment (post)
RESIST-TB will host a webinar on 14 April 2022 on the latest results in the recent studies reporting on pretomanid-containing regimens, ZeNiX and TB-PRACTECAL, for the treatment of multidrug-resistant TB (MDR-TB).
TB resistance to bedaquiline when it's not reserved as last resource (post)
Bedaquiline-resistant tuberculosis is characterized in South Africa, where it has not been reserved as last resource for drug-resistant TB.
Recently developed drugs for the treatment of drug-resistant TB: a research and development case study (post)
In an article published in the journal BMJ Global Health, authors from the Médecins Sans Frontières (MSF) Access Campaign analyse the development and approval of two newer drugs for treating drug-resistant tuberculosis (DR-TB), bedaquiline and delamanid, in the current pharmaceutical research and development (R&D) paradigm, and the failure of the regulatory approval process to define the drugs’ role in multidrug regimens to improve treatment outcomes.
Webinar: Discussion of 6-month MDR-TB treatment - recording now available online (post)
RESIST-TB conducted a webinar on 14 April 2022 on the latest results in the recent studies reporting on pretomanid-containing regimens, ZeNiX and TB-PRACTECAL, for the treatment of multidrug-resistant TB (MDR-TB).
RESIST-TB April 2022 newsletter (post)
RESIST-TB released its April 2022 newsletter with the latest research publications on drug-resistant TB.
WHO: Call for expressions of interest (post)
The World Health Organization (WHO) is seeking expressions of interest from individuals or entities with relevant expertise to perform a systematic review of the evidence for the diagnostic accuracy of targeted next-generation sequencing technologies for detection of drug resistance among people diagnosed with TB.
Page 74 of 117 · Total posts: 0
←First 73 74 75 Last→